Literature DB >> 20184966

Cochlear implantation: an opportunity for drug development.

Hinrich Staecker1, Claude Jolly, Carolyn Garnham.   

Abstract

For many years, the fields of inner ear pharmacology and hearing devices have progressed in parallel with limited interaction. Recently, there has been a considerable advancement in our understanding of the inner ear and its pathologies. Cochlear implantation is now being adapted for patients with considerable residual hearing but minimal benefit from hearing aids. A major consequence is the recognition that devices can be implanted into the partially deaf inner ear with minimal loss of hearing. This opens the door to the concept of local drug treatment of the inner ear using implantable devices. The evolution of cochlear implantation thus presents us with an opportunity to develop a range of local pharmacologic interventions to prevent hearing degeneration. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20184966     DOI: 10.1016/j.drudis.2010.02.005

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  11 in total

Review 1.  The convergence of cochlear implantation with induced pluripotent stem cell therapy.

Authors:  Niliksha Gunewardene; Mirella Dottori; Bryony A Nayagam
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

2.  AAV-Mediated Neurotrophin Gene Therapy Promotes Improved Survival of Cochlear Spiral Ganglion Neurons in Neonatally Deafened Cats: Comparison of AAV2-hBDNF and AAV5-hGDNF.

Authors:  Patricia A Leake; Stephen J Rebscher; Chantale Dore'; Omar Akil
Journal:  J Assoc Res Otolaryngol       Date:  2019-06-20

Review 3.  Microsystems technologies for drug delivery to the inner ear.

Authors:  Erin E Leary Pararas; David A Borkholder; Jeffrey T Borenstein
Journal:  Adv Drug Deliv Rev       Date:  2012-02-21       Impact factor: 15.470

Review 4.  Intracochlear drug delivery systems.

Authors:  Jeffrey T Borenstein
Journal:  Expert Opin Drug Deliv       Date:  2011-05-26       Impact factor: 6.648

5.  Promontorial cochleostomy in nonhuman primates. Is it atraumatic?

Authors:  Raquel Manrique; Sebastián E Picciafuoco; Francisco Javier Cervera-Paz; Nicolás Pérez; Manuel J Manrique
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-01-05       Impact factor: 2.503

6.  Brain-derived neurotrophic factor promotes cochlear spiral ganglion cell survival and function in deafened, developing cats.

Authors:  Patricia A Leake; Gary T Hradek; Alexander M Hetherington; Olga Stakhovskaya
Journal:  J Comp Neurol       Date:  2011-06-01       Impact factor: 3.215

7.  Kinetics of reciprocating drug delivery to the inner ear.

Authors:  Erin E Leary Pararas; Zhiqiang Chen; Jason Fiering; Mark J Mescher; Ernest S Kim; Michael J McKenna; Sharon G Kujawa; Jeffrey T Borenstein; William F Sewell
Journal:  J Control Release       Date:  2011-03-06       Impact factor: 9.776

8.  Effects of brain-derived neurotrophic factor (BDNF) and electrical stimulation on survival and function of cochlear spiral ganglion neurons in deafened, developing cats.

Authors:  Patricia A Leake; Olga Stakhovskaya; Alexander Hetherington; Stephen J Rebscher; Ben Bonham
Journal:  J Assoc Res Otolaryngol       Date:  2013-02-08

9.  Mesenchymal stem cells for sensorineural hearing loss: a systematic review of preclinical studies.

Authors:  Kevin Chorath; Matthew Willis; Nicolas Morton-Gonzaba; Alvaro Moreira
Journal:  Mol Biol Rep       Date:  2020-04-22       Impact factor: 2.316

Review 10.  Neurotrophin gene therapy to promote survival of spiral ganglion neurons after deafness.

Authors:  Patricia A Leake; Omar Akil; Hainan Lang
Journal:  Hear Res       Date:  2020-04-05       Impact factor: 3.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.